Clinical Trial Update: Beta 3 Agonist Treatment in Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a beta-3 agonist in chronic heart failure with reduced ejection fraction (HFrEF) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Beta 3 agonist (beta-3 agonist)

Snippet

Sponsor: Henning Bundgaard | Conditions: Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) | Phase 2 | Status: COMPLETED